Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

[Q]: Context: Coming off their Sunday night road win over the Packers, the Cowboys went home for a Week 4 NFC East showdown with the Washington Redskins. In the first quarter, the 'Boys shot first as QB Tony Romo completed a 21-yard TD pass to TE Jason Witten. In the second quarter, the Redskins took the lead as QB Jason Campbell completed a 3-yard TD pass to WR James Thrash and a 2-yard TD pass to WR Antwaan Randle El, along with kicker Shaun Suisham getting a 20-yard field goal. Dallas closed out the half with kicker Nick Folk getting a 36-yard field goal. In the third quarter, the Cowboys tied the game with Romo completing a 10-yard TD pass to WR Terrell Owens. Washington would respond with Suisham kicking a 33-yard field goal. In the fourth quarter, the Redskins increased their lead with Suisham nailing a 33-yard and a 29-yard field goal. The 'Boys tried to rally as Romo completed an 11-yard TD pass to WR Miles Austin. However, Dallas' onside kick attempt failed, preserving the Redskins' win. 
 Question: In what quarter was the longest touchdown pass?
[A]: first


[Q]: Context: From a human point of view, natural resources can be classified as either renewable or nonrenewable. Renewable resources are natural resources that are remade by natural processes as quickly as people use them. Examples of renewable resources include sunlight and wind. They are in no danger of being used up. Metals and some other minerals are considered renewable as well because they are not destroyed when they are used. Instead, they can be recycled and used over and over again. Living things are also renewable resources. They can reproduce to replace themselves. However, living things can be over-used or misused to the point of extinction. For example, over-fishing has caused some of the best fishing spots in the ocean to be nearly depleted, threatening entire fish species with extinction. To be truly renewable, living things must be used wisely. They must be used in a way that meets the needs of the present generation but also preserves them for future generations. Using resources in this way is called sustainable use. Nonrenewable resources are natural resources that cant be remade or else take too long to remake to keep up with human use. Examples of nonrenewable resources are coal, oil, and natural gas, all of which are fossil fuels. Fossil fuels form from the remains of plants and animals over hundreds of millions of years. We are using them up far faster than they can be replaced. At current rates of use, oil and natural gas will be used up in just a few decades, and coal will be used up in a couple of centuries. Uranium is another nonrenewable resource. It is used to produce nuclear power. Uranium is a naturally occurring chemical element that cant be remade. It will run out sooner or later if nuclear energy continues to be used. Soil is a very important natural resource. Plants need soil to grow, and plants are the basis of terrestrial ecosystems. Theoretically, soil can be remade. However, it takes millions of years for soil to form, so from a human point of view, it is a nonrenewable resource. Soil can be misused and eroded (see Figure 25.9). It must be used wisely to preserve it for the future. This means taking steps to avoid soil erosion and contamination of soil by toxins such as oil spills. Some of the resources we depend on the most are energy resources. Whether its powering our lights and computers, heating our homes, or providing energy for cars and other vehicles, its hard to imagine what our lives would be like without a constant supply of energy. Fossil fuels and nuclear energy are nonrenewable energy resources. People worldwide depend far more on these energy sources than any others. Figure 25.10 shows the worldwide consumption of energy sources by type in 2010. Nonrenewable energy sources accounted for 83 percent of the total energy used. Fossil fuels and the uranium needed for nuclear power will soon be used up if we continue to consume them at these rates. Using fossil fuels and nuclear energy creates other problems as well. The burning of fossil fuels releases carbon dioxide into the atmosphere. This is one of the major greenhouse gases causing global climate change. Nuclear power creates another set of problems, including the disposal of radioactive waste. Switching to renewable energy sources solves many of the problems associated with nonrenewable energy. While it may be expensive to develop renewable energy sources, they are clearly the way of the future. Figure 25.11 represents three different renewable energy sources: solar, wind, and biomass energy. The three types are described below. You can watch Bill Nyes introduction to renewable energy resources in this video: MEDIA Click image to the left or use the URL below. URL: Solar energy is energy provided by sunlight. Solar cells can turn sunlight into electricity. The energy in sunlight is virtually limitless and free and creates no pollution to use. Wind energy is energy provided by the blowing wind. Wind turbines, like those in Figure 25.11, can turn wind energy into electricity. The wind blows because of differences in heating of Earths atmosphere by the sun. There will never be a shortage of wind. Biomass energy is energy provided by burning 
 Question: If natural gas continues to be used at current rates, it will be used up in a few
[A]: decades.


[Q]: Context: Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase involved in signalling in many of the cells that drive immune inflammation. The development of small molecules that inhibit Syk kinase may change the way we treat disorders such as rheumatoid arthritis (RA), as well as a range of other inflammatory diseases. Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. Fostamatinib was developed because it has more favourable physiochemical properties. It is rapidly converted to R406 by intestinal enterocytes. It has been evaluated in experimental models of RA, such as collagen-induced arthritis. In these models, fostamatinib suppressed clinical arthritis, bone erosions, pannus formation and synovitis. A phase II programme with fostamatinib has largely been completed. Three key trials have been published, lasting 12-26 weeks and each enrolling 189-457 patients (875 in total). All these trials involved placebo therapy and patients continued to receive methotrexate in addition to active treatment with fostamatinib. The first dose-ranging trial evaluated three treatment doses in RA patients who had not fully responded to methotrexate therapy. The second trial compared two treatment doses in patients who had not responded to methotrexate therapy. The third trial compared a single treatment dose with placebo in patients who had not responded to biological therapy. The primary outcome measure was the number of patients achieving American College of Rheumatology (ACR) 20% (ACR20) responses. Placebo ACR20 response rates in all three trials were similar (35-38%). All three trials involved one treatment arm receiving fostamatinib 100 mg twice daily; ACR20 responses with this active treatment ranged from 38% to 67%. A meta-analysis of ACR responses in these trials, using responses to the highest dose in each trial for comparisons with placebo therapy in a random effects model, showed a borderline benefit with ACR20 responses. There were more significant differences with ACR50 and ACR70 responses. The reason that this meta-analysis was not more strongly positive is that the third trial, which evaluated patients who had failed to respond to biological treatments, gave negative results. Individual ACR response components, such as changes in swollen joint counts, showed significant differences in the first two trials, but there were no definite treatment benefits in the third trial. Overall, the differences were significant in a meta-analysis of all three trials. The most important adverse reactions were diarrhoea, neutropenia and raised ALT levels, which all showed significant excesses with active treatment compared with placebo. Too few patients have been studied for a definitive safety profile to be known. Overall, the results of the phase II trials were sufficiently encouraging for a phase III programme to be initiated. It will be some years before their definitive results are available. 
 Question: Which enzyme is inhibited by a drug fostamatinib?
[A]:
spleen tyrosine kinase